130 related articles for article (PubMed ID: 36976639)
1. FDG PET/CT in a Case of Pure Ductal Adenocarcinoma of the Prostate With Osteolytic Metastases and Normal PSA Level.
Dong A; Lin X; Bai Y; Yang B; Xu S
Clin Nucl Med; 2023 Jul; 48(7):640-642. PubMed ID: 36976639
[TBL] [Abstract][Full Text] [Related]
2. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
3. 68 Ga-PSMA-11 and 18 F-FDG PET/CT in a Case of Ductal Adenocarcinoma of the Prostate.
Qiu S; Dong A; Zhu Y; Zuo C
Clin Nucl Med; 2022 Sep; 47(9):836-838. PubMed ID: 35439204
[TBL] [Abstract][Full Text] [Related]
4. Comparison of bone scintigraphy and 18F-FDG PET-CT in a prostate cancer patient with osteolytic bone metastases.
Ozcan Kara P; Kara T; Kara Gedik G; Sari O; Sahin O
Rev Esp Med Nucl; 2011; 30(2):94-6. PubMed ID: 21342722
[TBL] [Abstract][Full Text] [Related]
5. FDG PET/CT in a Case With Primary Poorly Differentiated Urothelial-Type Adenocarcinoma of the Prostate.
Dong A; Zhu Y; Zuo C
Clin Nucl Med; 2022 Aug; 47(8):736-738. PubMed ID: 35797631
[TBL] [Abstract][Full Text] [Related]
6. Lung Metastasis From Prostate Cancer Revealed by 18F-FDG PET/CT Without Osseous Metastasis on Bone Scan.
Su HY; Chen ML; Hsieh PJ; Hsieh TS; Chao IM
Clin Nucl Med; 2016 May; 41(5):392-3. PubMed ID: 26859201
[TBL] [Abstract][Full Text] [Related]
7. Positron emission tomography with 11C-acetate and 18F-FDG in prostate cancer patients.
Fricke E; Machtens S; Hofmann M; van den Hoff J; Bergh S; Brunkhorst T; Meyer GJ; Karstens JH; Knapp WH; Boerner AR
Eur J Nucl Med Mol Imaging; 2003 Apr; 30(4):607-11. PubMed ID: 12589476
[TBL] [Abstract][Full Text] [Related]
8. Prostate-Specific Membrane Antigen-Avid Bone Metastases From Urothelial Carcinoma of the Bladder.
Zhao B; Dong A; Zuo C
Clin Nucl Med; 2022 Oct; 47(10):892-894. PubMed ID: 35439183
[TBL] [Abstract][Full Text] [Related]
9. 18F-FDG PET/CT superscan in prostate cancer.
Bailly M; Besse H; Kerdraon R; Metrard G; Gauvain S
Clin Nucl Med; 2014 Oct; 39(10):912-4. PubMed ID: 24566401
[TBL] [Abstract][Full Text] [Related]
10. Non-Prostate-Specific Membrane Antigen-Avid Metastatic Lung Nodule From Primary Prostatic Adenocarcinoma.
Shetty D; Loh H; Bui C; Mansberg R; Hadjashrafi A; Do V
Clin Nucl Med; 2016 Oct; 41(10):776-8. PubMed ID: 27556788
[TBL] [Abstract][Full Text] [Related]
11. [18F]Fluorodeoxyglucose positron emission tomography surveillance of hepatic metastases from prostate cancer following radiofrequency ablation: a case report.
Ludwig V; Hopper OW; Martin WH; Kikkawa R; Delbeke D
Am Surg; 2003 Jul; 69(7):593-8. PubMed ID: 12889623
[TBL] [Abstract][Full Text] [Related]
12. [PET/CT with (11)C-choline and (18)F-FDG in patients with elevated PSA after radical treatment of a prostate cancer].
García JR; Soler M; Blanch MA; Ramírez I; Riera E; Lozano P; Pérez X; Delgado E; Carrio I; Lomeña F
Rev Esp Med Nucl; 2009; 28(3):95-100. PubMed ID: 19558948
[TBL] [Abstract][Full Text] [Related]
13. Prostate-Specific Membrane Antigen Uptake Heterogeneity in Mixed Ductal-Acinar Adenocarcinoma of the Prostate.
Zhao Q; Dong A; Bai Y; Zuo C
Clin Nucl Med; 2023 Aug; 48(8):750-752. PubMed ID: 37290403
[TBL] [Abstract][Full Text] [Related]
14. Combined 18F-FDG and 11C-methionine PET scans in patients with newly progressive metastatic prostate cancer.
Nuñez R; Macapinlac HA; Yeung HW; Akhurst T; Cai S; Osman I; Gonen M; Riedel E; Scher HI; Larson SM
J Nucl Med; 2002 Jan; 43(1):46-55. PubMed ID: 11801702
[TBL] [Abstract][Full Text] [Related]
15. Detecting metastatic pelvic lymph nodes by 18F-2-deoxyglucose positron emission tomography in patients with prostate-specific antigen relapse after treatment for localized prostate cancer.
Chang CH; Wu HC; Tsai JJ; Shen YY; Changlai SP; Kao A
Urol Int; 2003; 70(4):311-5. PubMed ID: 12740497
[TBL] [Abstract][Full Text] [Related]
16. Fluorodeoxyglucose positron emission tomography studies in the diagnosis and staging of clinically advanced prostate cancer.
Sung J; Espiritu JI; Segall GM; Terris MK
BJU Int; 2003 Jul; 92(1):24-7. PubMed ID: 12823377
[TBL] [Abstract][Full Text] [Related]
17. Discordant findings in patients with non-small-cell lung cancer: absolutely normal bone scans versus disseminated bone metastases on positron-emission tomography/computed tomography.
Ak I; Sivrikoz MC; Entok E; Vardareli E
Eur J Cardiothorac Surg; 2010 Apr; 37(4):792-6. PubMed ID: 20015657
[TBL] [Abstract][Full Text] [Related]
18. FDG PET/CT in Peritoneal Metastasis From Prostate Cancer.
Gungor S; Asa S; Kupik O
Clin Nucl Med; 2016 Sep; 41(9):e424-5. PubMed ID: 27187732
[TBL] [Abstract][Full Text] [Related]
19. Localizing sites of disease in patients with rising serum prostate-specific antigen up to 1ng/ml following prostatectomy: How much information can conventional imaging provide?
Vargas HA; Martin-Malburet AG; Takeda T; Corradi RB; Eastham J; Wibmer A; Sala E; Zelefsky MJ; Weber WA; Hricak H
Urol Oncol; 2016 Nov; 34(11):482.e5-482.e10. PubMed ID: 27346339
[TBL] [Abstract][Full Text] [Related]
20. Heterogeneous uptake of
Hu Y; Wang P; Dai W
BMC Pulm Med; 2023 Mar; 23(1):73. PubMed ID: 36882747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
